Pharmaceuticals - Uganda

Uganda

In Uganda, the revenue in the Pharmaceuticals market is estimated to reach US$301.70m in 2024.
The largest market within this industry is Oncology Drugs, which is projected to have a market volume of US$51.16m in 2024.
Looking ahead, the revenue is expected to exhibit an annual growth rate (CAGR 2024-2028) of 4.36%, resulting in a market volume of US$357.90m by 2028.
When compared globally, United States is anticipated to generate the highest revenue in the Pharmaceuticals market, with an estimated amount of US$636.90bn in 2024.
Uganda's pharmaceutical market is experiencing a surge in demand for affordable generic medications.

Key regions: United States, China, Germany, Japan, Europe

Definition:
The Pharmaceuticals market covers remedies used to cure, treat, prevent, and diagnose diseases. These small molecule drugs or biologic medical products may be called drugs, medications, or medicines. Prescription drugs and over-the-counter (OTC) drugs are both included. Depending on the regulations in each country, these products are provided by pharmacies, hospitals, physicians, and/or drug stores, and/or they can be bought elsewhere. They may be administered in the form of pills, capsules, gels, ointments, injections, infusions, lozenges, or aerosols/sprays.

Structure:
The market is subdivided into Oncology Drugs, Anti-Diabetes Drugs, Anti-Rheumatic Drugs, Vaccines, Dermatological Drugs, Antiviral Drugs, Immunosuppressants, Bronchodilator Drugs, Sensory Organ Drugs, Anti-Hypertensive Drugs, Anti-Coagulants, Anti-Fibrinolytic Drugs, Multiple Sclerosis Drugs, Lipid-Lowering Agents and Other Pharmaceuticals. The Pharmaceuticals market is organized in markets that cover drugs used in specific medical fields, i.e., medicines for a specific disesase or a certain type of medicine. They include original brands, biosimilars, generics, and orphan drugs.The Oncology Drugs market covers pharmaceutical products specifically developed for the treatment and management of various cancers. The Anti-Diabetes Drugs market covers medications designed to manage blood glucose levels and improve insulin sensitivity in individuals with diabetes. The market Anti-Rheumatic Drugs includes pharmaceuticals specifically developed to alleviate symptoms, reduce inflammation, and modify the progression of rheumatic diseases. The Dermatological Drugs market covers pharmaceuticals formulated to treat and manage a wide range of skin conditions such as eczema, acne, and rosacea. The Antiviral Drugs market includes medications designed to treat viral infections and reducing the severity and duration of symptoms. The Immunosuppressants market covers pharmaceuticals that suppress the immune system's activity. The Bronchodilator Drugs market covers pharmaceuticals designed to relax and widen the airways in the lungs. The Sensory Organ Drugs market covers pharmaceuticals targeting the treatment of disorders and conditions affecting sensory organs such as the eyes, ears and nose. The Anti-hypertensive Drugs market covers pharmaceuticals designed to lower blood pressure levels. The Anti-Coagulants Drugs market covers pharmaceuticals developed to prevent the formation of blood clots or to dissolve existing clots. The Anti-Fibrinolytics Drugs market covers pharmaceuticals designed to inhibit the breakdown of blood clots. The Multiple Sclerosis Drugs market covers pharmaceuticals aimed at managing and modifying the course of multiple sclerosis. The Lipid-Lowering Agents market covers pharmaceuticals developed to reduce levels of cholesterol and other lipids in the blood. The Other Pharmaceuticals market provides information on additional specialties that are not covered by the main markets.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novartis, Roche, Pfizer, Merck & Co, Johnson & Johnson, AbbVie, Sanofi.

Market

Region

Region comparison

Currency

Analyst Opinion

The Pharmaceuticals market in Uganda has experienced steady growth in recent years.

Customer preferences: Uganda's population is growing, and with it, the demand for healthcare services is increasing. There is a growing preference for high-quality healthcare services, which has led to an increase in demand for pharmaceutical products. There is also a growing trend towards the use of generic drugs, which are more affordable than their branded counterparts.

Trends in the market: One of the major trends in the pharmaceuticals market in Uganda is the increasing number of local manufacturers. This has led to increased competition and lower prices for consumers. Another trend is the growing demand for over-the-counter (OTC) drugs, which can be purchased without a prescription. This is driven by the increasing availability of information about healthcare products and the growing consumer awareness of the benefits of preventive healthcare.

Local special circumstances: Uganda has a relatively low level of healthcare spending, which has led to a shortage of healthcare facilities and trained healthcare professionals. This has created a gap in the market for private healthcare providers, who are increasingly catering to the needs of the population. There is also a growing trend towards self-medication, which is driven by the lack of access to healthcare facilities and the high cost of prescription drugs.

Underlying macroeconomic factors: Uganda's economy has been growing steadily in recent years, which has led to an increase in disposable income and a growing middle class. This has created a larger market for pharmaceutical products, as more people are able to afford healthcare services. In addition, the government has been investing in the healthcare sector, which has led to improvements in healthcare infrastructure and the availability of healthcare services. However, there are still challenges in the market, including a lack of regulation and the presence of counterfeit drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.